Constanze Jonak
MD
Associate Professor of Dermatology
👥Biography 个人简介
Constanze Jonak was among the investigators contributing to the ALCANZA trial that established brentuximab vedotin as superior to physician's choice therapy (methotrexate or bexarotene) in CD30-expressing MF and primary cutaneous ALCL. Her research addresses CD30 expression patterns and heterogeneity in CTCL, clinical utility of CD30 as a predictive biomarker, and outcomes following brentuximab vedotin in European CTCL cohorts.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Constanze Jonak 的研究动态
Follow Constanze Jonak's research updates
留下邮箱，当我们发布与 Constanze Jonak（Medical University of Vienna）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment